SCHEMBL8274763

SCHEMBL8274763

CN(C(=O)OC(C)(C)C)C1Cc2ccccc2N(Cc2ccc(F)cc2)C1=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.44
▸ KMT2A Q03164 1/20 0.44
▸ DRD2 P14416 4/20 0.42
▸ DRD4 P21917 4/20 0.42
▸ SCN9A Q15858 1/20 0.40
▸ NPY1R P25929 1/20 0.39
▸ SMN1; SMN2 Q16637 3/20 0.38
▸ HDAC6 Q9UBN7 3/20 0.38
▸ TP53 P04637 2/20 0.38
▸ HDAC1 Q13547 2/20 0.38
▸ THRB P10828 1/20 0.38
▸ HDAC4 P56524 1/20 0.37
▸ HDAC7 Q8WUI4 1/20 0.37
▸ HDAC2 Q92769 1/20 0.37
▸ HDAC10 Q969S8 1/20 0.37
▸ TSHR P16473 1/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ LMNA P02545 1/20 0.37
▸ HTT P42858 1/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24001743 0.79 EGFR (0.43) KMT2ASCN9ANPY1RTSHRKDM4E
SCHEMBL8273839 0.75 XIAP (0.43) MEN1KMT2A
SCHEMBL8276173 0.72 MEN1 (0.53) MEN1KMT2ADRD2DRD4NPY1R
SCHEMBL5310034 0.71 CYP1A2 (0.41) MEN1KMT2ATSHRHTT
SCHEMBL7416762 0.70 NPY1R (0.59) KMT2ASCN9ANPY1R
SCHEMBL5132571 0.70 NPY1R (0.59) KMT2ASCN9ANPY1R
SCHEMBL7933782 0.69 FNTA (0.44) KMT2AHDAC6HDAC1
SCHEMBL4344066 0.69 DRD2 (0.46) MEN1KMT2ADRD2DRD4
SCHEMBL7417336 0.68 NPY1R (0.51) DRD2DRD4SCN9ANPY1R
SCHEMBL4899362 0.68 MEN1 (0.42) MEN1KMT2ASMN1; SMN2TP53LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080009512-A1 Tetrahydroquinolones and Aza-Analogues Thereof for Use as Dpp-IV Inhibitors in the Treatment of Diabetes ASTRAZENECA AB (SE) 2008-01-10 — — US disclosed
US-20080009512-A1 Tetrahydroquinolones and Aza-Analogues Thereof for Use as Dpp-IV Inhibitors in the Treatment of Diabetes ASTRAZENECA AB (SE) 2008-01-10 — — US disclosed
WO-2005123685-A1 TETRAHYDROQUINOLONES AND AZA-ANALOGUES THEREOF FOR USE AS DPP-IV INHIBITORS IN THE TREATEMENT OF DIABETES ASTRAZENECA AB (SE) 2005-12-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080009512-A1 Tetrahydroquinolones and Aza-Analogues Thereof for Use as Dpp-IV Inhibitors in the Treatment of Diabetes DPP4, DPP8, DPP3 MEN1 2942/4885KMT2A 911/4885DRD2 720/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback